HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab

Although current breast cancer treatment guidelines limit the use of HER2 blocking agents to tumors with HER2 gene amplification, recent retrospective analyses suggest that a wider group of patients may benefit from this therapy. Utilizing breast cancer cell lines, mouse xenograft models and matched...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ithimakin, Suthinee, Day, Kathleen C., Malik, Fayaz, Zen, Qin, Dawsey, Scott J., Bersano-Begey, Tom F., Quraishi, Ahmed A., Ignatoski, Kathleen Woods, Daignault, Stephanie, Davis, April, Hall, Christopher L., Palanisamy, Nallasivam, Heath, Amber N., Tawakkol, Nader, Luther, Tahra K., Clouthier, Shawn G., Chadwick, Whitney A., Day, Mark L., Kleer, Celina G., Thomas, Dafydd G., Hayes, Daniel F., Korkaya, Hasan, Wicha, Max S.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600586/
https://ncbi.nlm.nih.gov/pubmed/23442322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3349
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items